NEW YORK (GenomeWeb) – Synthetic biology firm Evonetix announced today that it has closed a $12.3 million financing round.

The financing was co-led by Data Collective and Draper Esprit, and included Morningside Group along with existing investors Providence Investment Company, Cambridge Consultants, Rising Tide Fund, and Civilization Ventures. Evonetix was spun out of Cambridge Consultants in 2016.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.